Adeno-associated virus (AAV) vectors have been explored extensively in numerous pre-clinical studies with varying degrees of success. A numberof these pre-clinical studies are now translating into encouraging results in phase l/ll clinical trials. In fact most recently, self-complementary (sc)AAV vectors have demonstrated sustained and potentially therapeutic levels of Factor IX in Phase I study of hemophilic B patients negative for pre-existing / AV Ab (ASH Nov 2010 &ASCGT 2011). With 90% ofthe human population naturally infected by AAV2, and 30-50% expressing NAb, contiuned success will require resolution of this problem. For these reasons Project 1 has focused on role of N/ b in AAVFIX gene transfer and describes a proposal to better understand the biology of Ab response to AAV capsids and to engineer novel molecular approaches to overcome these limitations. HLA class II phenotypes play a major role in antigen presentation to induce antibody production. Although almost every individual produces AAV specific immunoglobulin, NAb is only detectable in half of the population, indicating that not all / AV-specific Abs produced possess neutralizing activity. To determine which HLA class II phenotypes are associated with AAV NAb production, we will screen the HLA-class II phenotypes, AAV specific immunoglobulins and AAV NAb profile in large number of human subjects (Aim 1). HLA-class II molecules bind to peptides of 12 to 18 aa and present the complex on antigen presenting cells to induce a humoral immune response. To further elucidate w/hich epitopes from AAV capsid are bound by NAb, we will use sera from St. Jude FIX trial (see let of support, Nathawni), AAV immunized HLA-class II transgenic mice and humans with NAb positive serum for this study (Aim 2). There are several approaches being considered to evade / AV NAb including chemical and genetic modification of AAV virion in the presence of neutralizing antibodies or randomly mutating AAV capsid. Based on the information from eiptope mapping, a novel aptamer selection against Ab will be explored (Aim 3). The broad objective of this proposal is to advance our understanding of capsid antigen presentation and examine therapies to circumvent major limitations imposed by systemic humoral immunity.

Public Health Relevance

Program Project 1 objective is to better understand /V^V capsid antigen biology in novel animal models of bleeding disorders and explore molecular approaches in hope of extending the clinical success seen with scAAV FIX.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
4P01HL112761-04
Application #
8990036
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2016-02-01
Budget End
2017-01-31
Support Year
4
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Chai, Zheng; Samulski, R Jude; Li, Chengwen (2018) Nab Escaping AAV Mutants Isolated from Mouse Muscles. Bio Protoc 8:
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Chai, Zheng; Zhang, Xintao; Rigsbee, Kelly Michelle et al. (2018) Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration. J Control Release 286:415-424
Tse, Longping V; Moller-Tank, Sven; Meganck, Rita M et al. (2018) Mapping and Engineering Functional Domains of the Assembly-Activating Protein of Adeno-associated Viruses. J Virol 92:
Albright, Blake H; Storey, Claire M; Murlidharan, Giridhar et al. (2018) Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol Ther 26:510-523
Berry, Garrett E; Tse, Longping V (2017) Virus Binding and Internalization Assay for Adeno-associated Virus. Bio Protoc 7:
Tse, Longping Victor; Klinc, Kelli A; Madigan, Victoria J et al. (2017) Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl Acad Sci U S A 114:E4812-E4821
Liang, Katharine J; Woodard, Kenton T; Weaver, Mark A et al. (2017) AAV-Nrf2 Promotes Protection and Recovery in Animal Models of Oxidative Stress. Mol Ther 25:765-779
Wang, M; Sun, J; Crosby, A et al. (2017) Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications. Gene Ther 24:49-59
Chai, Zheng; Sun, Junjiang; Rigsbee, Kelly Michelle et al. (2017) Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion. J Control Release 262:348-356

Showing the most recent 10 out of 46 publications